Aegates objective is to ensure that European stakeholders engaged in implementing the EU Falsified Medicines Directive (EU FMD) receive accessible and transparent support grounded in our experience of delivering medicines verification services for the past 10 years.
I look forward to leading Aegate to best support the industry through this transition and to realise the full benefits of medicines authentication.
Today, David leads the development and provision of Aegates
services in secondary care, pharmacovigilance, bio-manufacturing and training.
John Rowley, CareMeds Managing Director added, We are delighted to be working with Aegate
and to be able to give added value to our customers through the application of Aegates
tried and tested service.